← All Arcutis Biotherapeutics, INC filings

Arcutis Biotherapeutics, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-Q: Arcutis Biotherapeutics Q3 2025: Revenue Soars, Net Income Returns
Arcutis Biotherapeutics reports significant revenue growth and a return to net income in Q3 2025, driven by strong ZORYVE product sales and strategic approvals.
NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-Q: Arcutis Reports Strong ZORYVE Sales, Narrows Q2 Loss
Arcutis Biotherapeutics significantly boosted product revenue and reduced its net loss in Q2 2025, driven by strong ZORYVE sales and new product approvals.
NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-Q: Arcutis Biotherapeutics Reports Strong Q1 2025 Revenue Growth Driven by ZORYVE Product Line
Arcutis Biotherapeutics' Q1 2025 revenue surged, fueled by robust sales of its ZORYVE cream and foam products, alongside licensing agreement revenues.
NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-Q: Arcutis Biotherapeutics Reports Strong Q3 Revenue Growth Driven by ZORYVE Product Sales
Arcutis Biotherapeutics saw a significant increase in revenue in the third quarter of 2024, primarily driven by sales of its ZORYVE product line.
NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-Q: Arcutis Biotherapeutics Reports Strong Q2 Revenue Growth Driven by ZORYVE Product Sales
Arcutis Biotherapeutics saw a significant increase in product revenue in the second quarter of 2024, primarily driven by sales of ZORYVE cream and foam.
NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-Q/A: Arcutis Biotherapeutics Files Amended Quarterly Report Due to Omitted Director Trading Plan Disclosure
Arcutis Biotherapeutics filed an amendment to its quarterly report to include a previously omitted Rule 10b5-1 trading plan by a board member.
NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-Q: Arcutis Biotherapeutics Reports Strong Q1 Revenue Growth Driven by ZORYVE Product Sales
Arcutis Biotherapeutics saw a significant increase in revenue in the first quarter of 2024, primarily driven by sales of its ZORYVE cream and foam products, alongside licensing revenue.